ASCO Genitourinary Cancers Symposium


 

ASCO GU 2022 on a Study EV-103 Cohort H: Antitumor Activity of Neoadjuvant Treatment With Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible MIBC

158 views
March 8, 2022
0 Comments
Login to view comments. Click here to Login